Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
Healthcare
$49.56 -0.96%
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
52W Low $32.53High $57.82
Volume 4.26M
Average 2.07M
Income Statement
Follow revenue through to earnings.
Revenue
$2.09B
FY 2025 · Annual
+5.7% YoYOperating Income
$520.31M
FY 2025 · Annual
+432.5% YoYNet Income
$424.88M
FY 2025 · Annual
+408.3% YoYIncome Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Cost of Revenue | 800.84M | 756.96M | 731.62M | 1.01B | 798.5M |
| Gross Profit | 1.45B | 1.38B | 1.23B | 967.35M | 1.29B |
| Gross Margin | 64.4% | 64.7% | 62.8% | 48.9% | 61.8% |
| Research & Development | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| Selling, General & Admin | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| Operating Expenses | 820.74M | 853.1M | 823.75M | 869.64M | 771.19M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| EBITDA | 895.24M | 779.36M | 688.56M | 368.26M | 717.27M |
| EBITDA Margin | 39.8% | 36.4% | 35.0% | 18.6% | 34.3% |
| Operating Income | 630.08M | 531.46M | 409.94M | 97.71M | 520.31M |
| Operating Margin | 28.0% | 24.8% | 20.9% | 4.9% | 24.9% |
| Interest Income | 9.56M | 32.76M | 78.99M | 68.02M | 64.32M |
| Interest Expense | 54.48M | 58.36M | 53.41M | 43.84M | 33.26M |
| Other Income / Expenses | (4.25M) | (18.86M) | 19.87M | 23.44M | (30.04M) |
| Income Before Tax | 625.83M | 512.6M | 429.81M | 121.15M | 490.27M |
| Pre-Tax Margin | 27.8% | 23.9% | 21.9% | 6.1% | 23.5% |
| Income Tax Expense | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Net Margin | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (Basic) | 2.52 | 2.08 | 1.67 | 0.39 | 2.04 |
| EPS (Diluted) | 2.47 | 2.05 | 1.65 | 0.38 | 2.04 |
| 221.14M | 220.75M | 217.49M | 216.44M | 207.94M | |
| 225.07M | 223.23M | 217.49M | 218.48M | 207.94M |
QGEN Earnings Waterfall · TTM
NYSE:QGEN · Revenue to Net Income
Key Ratios
EPS$1.95
Gross Margin61.9%
Net Margin19.4%
P/E Ratio22.8
P/S Ratio17.1
Analysis
$2.1B of revenue converted into $409.3M of net income for the selected period. Gross margin is 61.9% and net margin is 19.4%, showing how much revenue survives after costs and taxes. EPS is $1.95, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Nov 6, 2026 | |
| SC TO-C | SC TO-C filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 23, 2026 |
How much revenue does QGEN generate?
Qiagen N.V. (QGEN) reported $2.09B of revenue in fiscal 2025.
Is QGEN profitable?
Qiagen N.V. (QGEN) reported $424.88M of net income, with a net margin of 20.3%.
Continue the stock analysis
Jump to another research area for this company.